Our IL-4-related signature can work as a molecular biomarker to classify glioma patients combined with current genetic biomarkers, which will be beneficial to predict survival more precisely and even can be used to predict clinical response to adjuvant therapies such as immunotherapy. This evidence concerns the gene IL4 and glioma.